Chinese PE Firm Shiyu Capital Leads $131M Series A Round In Biotech Start-Up

Lepu Biotech, a Chinese biotechnology firm specialized in tumor immunotherapy, has raised RMB900 million (US$131.47 million) in a series A round of financing led by the country’s healthcare-focused private equity firm Shiyu Capital, according to a statement released on Monday.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!

Already have an account or paid subscription? Log in

China Expert network